论文部分内容阅读
一、肺血管扩张药的适应症 (一)原发性肺动脉高压症 肺血管扩张药的真正适应症是原发性肺动脉高压症。几乎所有的肺血管扩张药,均企图以本病为目的。肺血管阻力增加,出现明显的肺动脉高压症,对外界刺激呈过敏状态,易出现肺血管痉挛。心导管等刺激,也有时伴有危险。年轻女性患者病情复杂,可于2至10年死亡,是预后不良的疾病。病理组织学方面,在肺血管的内膜和中膜可见器质性病变。在典型病例中,可出现所谓中膜肌层的肥大和增殖,称为肌性动脉化。中膜肌层发达是原发性肺动脉高血压症病因的一部分?还是它的结果?还不完全明白。肌性动脉中膜肥厚,认为与肺血管的机能性收缩有关。解除这种肺小血管的能动性收缩所用的药物,就是肺血管扩张剂的本义。现将对原发性肺动脉压报告有效的药物汇集于下:
First, the indications of pulmonary vasodilator (A) of the primary indications of pulmonary vasodilator primary pulmonary hypertension is primary pulmonary hypertension. Almost all pulmonary vasodilator drugs, are intended to the disease for the purpose. Pulmonary vascular resistance increased, there was significant pulmonary hypertension, allergic to the external state was stimulated, prone to pulmonary vasospasm. Cardiac catheter and other stimuli, sometimes accompanied by danger. Young female patients with complex conditions, can be 2 to 10 years of death, is a poor prognosis of the disease. Histopathology, in the pulmonary vascular intima and mediastinal organic lesions can be seen. In a typical case, so-called hypertrophy and proliferation of the medial myometrium can occur, known as muscular arteries. The development of the muscularis propria is part of the etiology of primary pulmonary hypertension or is the result? Not fully understood yet. Medial hypertrophy of the muscular arteries is thought to be related to the functional contractions of the pulmonary vasculature. Drugs used to lift the active contractions of this small pulmonary artery are the original meaning of pulmonary vasodilators. The drugs that report on primary pulmonary hypertension are now pooled: